GIPM
IRMD icon

G2 Investment Partners Management’s iRadimed IRMD Stock Holding History

G2 Investment Partners Management’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-61,326
Closed -$2.75M – 84
2022
Q1 		$2.75M Buy
61,326
+50,699
+477% +$2.34M 0.65% 48
2021
Q4 		$491K Buy
+10,627
New +$429K 0.08% 78

Other funds holding IRMD

NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMC
RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

G2 Investment Partners Management's IRMD Position: Q2 2022 in Review

G2 Investment Partners Management sold out of iRadimed (IRMD) in Q2 2022, closing a stake of 61,326 shares — an estimated $2.75M sold.

G2 Investment Partners Management first reported a position in IRMD in Q4 2021 and held it in 2 quarters. The position peaked at $2.75M in Q1 2022. 90 funds tracked by Wall St. Rank hold IRMD as of Q2 2022.

  • G2 Investment Partners Management reported no remaining iRadimed position as of Q2 2022 after selling out during the quarter.
  • G2 Investment Partners Management sold 61,326 iRadimed shares in Q2 2022, an estimated $2.75M.
  • G2 Investment Partners Management first reported a position in iRadimed in Q4 2021 and held it in 2 quarters.
  • G2 Investment Partners Management's iRadimed position peaked at $2.75M in Q1 2022.
  • 90 funds tracked by Wall St. Rank held iRadimed as of Q2 2022.

Based on G2 Investment Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.